Gilead Stalled On HIV Prevention Approval For Truvada

Law360, New York (June 8, 2012, 5:13 PM EDT) -- The U.S. Food and Drug Administration has delayed by three months a decision on whether Gilead Sciences Inc. can expand the indications for its HIV drug Truvada to include prevention of the virus in uninfected people, Gilead said Friday.

The regulator, which had been expected to decide on the matter within about the next week, has put off a decision until Sept. 14 so that it can review a new strategy for reducing risks associated with the expanded use of Truvada that Gilead submitted to the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.